Header

UZH-Logo

Maintenance Infos

Response to tyrosine kinase hnhibitors in myeloproliferative neoplasia with 8p11 translocation and CEP110-FGFR1 rearrangement


Wehrli, M; Oppliger Leibundgut, E; Gattiker, H H; Manz, Markus G; Müller, A M; Goede, J S (2017). Response to tyrosine kinase hnhibitors in myeloproliferative neoplasia with 8p11 translocation and CEP110-FGFR1 rearrangement. The Oncologist, 22(4):480-483.

Abstract

This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation

Abstract

This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation

Statistics

Citations

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Hematology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Acute myeloid leukemia, CEP110‐FGFR1 fusion protein, Dasatinib, Eosinophilia, Imatinib
Language:English
Date:April 2017
Deposited On:30 Oct 2017 16:11
Last Modified:12 Sep 2018 10:42
Publisher:AlphaMed Press
ISSN:1083-7159
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1634/theoncologist.2016-0354
PubMed ID:28242791

Download

Full text not available from this repository.
View at publisher

Get full-text in a library